



Once you have made the clinical decision
to prescribe a Johnson & Johnson medicine,
support is available

J&J withMe

Helping you support your
patients living with cancer

J&J withMe is your single source for access,
affordability, and treatment support programs
from Johnson & Johnson.

 **DARZALEX®**
(daratumumab)
Injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

 **DARZALEX Faspro®**
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000 units

 **TECVAYLI®**
(teclistamab-cqyv) Injection for
subcutaneous use
10 mg/mL and 90 mg/mL

 **TALVEY®**
(talquetamab-tgvs)
Injection for
subcutaneous use
2 mg/mL and 40 mg/mL

 **Akeega®**
(niraparib/abiraterone acetate)
100mg/500mg tablets • 50mg/500mg tablets

 **Erleada®**
(apalutamide) 60 mg tablets
240 mg tablet

 **RYBREVANT Faspro™**
(amivantamab and hyaluronidase-lpuj)
Subcutaneous injection | 1,600 mg/20,000 units | 2,240 mg/28,000 units

 **RYBREVANT®**
(amivantamab-vmjw)
Injection for IV Use | 350 mg/7 mL (50 mg/mL)

 **LAZCLUZE™**
(lazertinib)
Tablets | 240 mg/80 mg

Please read full Prescribing Information for **DARZALEX®**, **DARZALEX FASPRO®**, **AKEEGA®**, **ERLEADA®**, **RYBREVANT FASPRO™**, **RYBREVANT®** and **LAZCLUZE™**, also available at [JNJwithMe.com](https://www.jnjwithme.com). Please read full Prescribing Information, including Boxed Warning, and Medication Guides for **TECVAYLI®** and **TALVEY®**, also available at [JNJwithMe.com](https://www.jnjwithme.com). Provide the Medication Guide to your patients and encourage discussion.

Johnson & Johnson



We can help make it simple for you to help your patients



For Your Office

J&J withMe provides your office with educational support to help patients throughout their treatment journey.

Access and Affordability Support:

- Benefits investigation support
- Prior authorization support and status monitoring
- Information on the exceptions and appeals process
- Coding and billing information
- Finding cost support options for eligible patients

Dedicated Support From a Field Reimbursement Manager:

- Access, fulfillment, and reimbursement education
- Information on cost support options for eligible patients
- Ability to connect with a specialty pharmacy in case of fulfillment issues



For Your Patients

Your patients will be connected with the program that aligns with their prescribed medicine from J&J. Support includes:



Cost support, including J&J withMe Savings Program and other resources



Free, dedicated 1-on-1 Care Navigator Support



Resources and community connections

For patient cost support enrollment for BALVERSA® (erdafitinib), visit Portal.JNJwithMe.com/express. Please read full Prescribing Information for [BALVERSA®](https://www.jnj.com/balversa), also available at [JNJwithMe.com](https://www.jnj.com/balversa).

J&J withMe

Click Below to Discover Patient Access and Affordability Options

MULTIPLE MYELOMA



PROSTATE



LUNG



Get started with J&J withMe:



Visit Portal.JNJwithMe.com

to investigate insurance coverage for your patients, enroll your patients in savings, or sign them up for Care Navigator support. Easy access to key support needs in **Provider Express** without an account, password, or Business Associate Agreement (BAA).



Visit JNJwithMe.com/hcp/

for access and affordability information for the J&J medicine you prescribed.

Bookmark these links for quick and easy access!



Call

833-JNJ-wMe1 (833-565-9631)
Monday through Friday, 8:00 AM to 8:00 PM ET

Please read full Prescribing Information for **DARZALEX®**, **DARZALEX FASPRO®**, **AKEEGA®**, **ERLEADA®**, **RYBREVANT FASPRO™**, **RYBREVANT®** and **LAZCLUZE™**, also available at JNJwithMe.com. Please read full Prescribing Information, including Boxed Warning, and Medication Guides for **TECVAYLI®** and **TALVEY®**, also available at JNJwithMe.com. Provide the Medication Guide to your patients and encourage discussion.

J&J withMe

Get started:



Visit

Portal.JNJwithMe.com



Call

833-JNJ-wMe1 (833-565-9631)

Monday through Friday

8:00 AM to 8:00 PM ET

OR



Visit

JNJwithMe.com/hcp/

Here's what patients think of the support provided by the J&J withMe Care Navigators:

98% of patients responded they were comfortable and prepared to start and continue treatment due to Care Navigator support.*



*Data on file. Johnson & Johnson Health Care Systems Inc. Findings through September 2023 (n=221).

The patient support and resources provided by J&J withMe are not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services, or serve as a reason to prescribe a J&J medicine.

© Johnson & Johnson Health Care Systems Inc. 2024 12/24 cp-475064v2

Johnson & Johnson